New drug combo shows promise for AML patients

NCT ID NCT05471700

Completed Disease control Sponsor: Zhujiang Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a combination of two drugs, azacitidine and venetoclax, in 40 adults aged 45 to 65 with newly diagnosed acute myeloid leukemia (AML). The goal was to see how safe and effective the combo is at shrinking the cancer. Participants received the drugs in 28-day cycles, and researchers measured how many achieved remission.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: azacitidine and venetoclax
What this could lead to: If successful, this combination could offer a new treatment option for acute myeloid leukemia, potentially improving remission rates.
What could go wrong: This is a small, single-arm study with no comparison group, so results may not be definitive. Side effects from the drugs are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOID, ACUTE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA, MYELOID, ACUTE

Contacts and locations

Locations

Nanfang Hospital of Southern Medical University

Guanzhou, Guandong, 510250, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.